Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Secukinumab 300 mg administered with an auto-injector ...
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...
RICHMOND, Va.--(BUSINESS WIRE)--Please replace the release dated March 2, 2022, with the following corrected version due to multiple revisions. The updated release ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results